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Abstract
Purpose—Recent studies suggest that intrinsic breast cancer subtypes may differ in their
responsiveness to specific chemotherapy regimens. We examined this hypothesis on NCIC.CTG
MA.5, a clinical trial randomizing premenopausal women with node-positive breast cancer to
adjuvant CMF (cyclophosphamide-methotrexate-fluorouracil) versus CEF (cyclophosphamide-
epirubicin-fluorouracil) chemotherapy.
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Experimental Design—Intrinsic subtype was determined for 476 tumors using the quantitative
reverse transcriptase PCR PAM50 gene expression test. Luminal A, luminal B, HER2-enriched
(HER2-E), and basal-like subtypes were correlated with relapse-free survival (RFS) and overall
survival (OS), estimated using Kaplan-Meier plots and log-rank testing. Multivariable Cox
regression analyses determined significance of interaction between treatment and intrinsic
subtypes.
Results—Intrinsic subtypes were associated with RFS (P = 0005) and OS (P < 0.0001) on the
combined cohort. The HER2-E showed the greatest benefit from CEF versus CMF, with absolute
5-year RFS and OS differences exceeding 20%, whereas there was a less than 2% difference for
non-HER2-E tumors (interaction test P = 0.03 for RFS and 0.03 for OS). Within clinically defined
Her2+ tumors, 79% (72 of 91) were classified as the HER2-E subtype by gene expression and this
subset was strongly associated with better response to CEF versus CMF (62% vs. 22%, P =
0.0006). There was no significant difference in benefit between CEF and CMF in basal-like
tumors [n = 94; HR, 1.1; 95% confidence interval (CI), 0.6−.1 for RFS and HR, 1.3; 95% CI,
0.7−2.5 for OS].
Conclusion—HER2-E strongly predicted anthracycline sensitivity. The chemotherapy-sensitive
basal- like tumors showed no added benefit for CEF over CMF, suggesting that nonanthracycline
regimens may be adequate in this subtype although further investigation is required.
Introduction
The common “intrinsic” subtypes of breast cancer as defined by gene expression analyses
have become known as luminal A (LumA), luminal B (LumB), HER2-enriched (HER2-E),
and basal like (1). The PAM50 gene set has become the standard for identifying these
subtypes and has shown prognostic significance when no adjuvant systemic therapy is given
(1), when patients receive adjuvant endocrine blockade only (2), and with different
chemotherapy regimens (1, 3). There has been little predictive data to support changing
chemotherapy based on “intrinsic” subtype, as few randomized clinical trials have been
tested. However, neoadjuvant chemotherapy studies have shown that, in general, basal-like
and HER2-E subtypes have the highest rates of pathologic response (1, 3).
Studies in patients with triple-negative disease have shown that these tumors are sensitive to
chemotherapy (3, 4). Furthermore, a number of retrospective analyses have suggested that
nonanthracycline chemotherapy may be particularly effective in the adjuvant treatment of
triple-negative cancers (5, 6). A biomarker analysis of the trial we present here (NCIC-CTG
MA.5; refs. 7, 8) concluded that the benefit of anthracycline treatment was primarily limited
to patients with Her2-amplified/overexpressed tumors (9) or TOP2A gene–altered (10)
tumors. A subsequently published meta-analysis, including more than 5,000 patients
randomized to anthracycline versus nonanthracycline chemotherapy, confirmed that
incorporating anthracyclines into chemotherapy regimens did not improve survival in Her2-
negative breast cancers (11). Although there are significant differences between genomic
subtyping by gene expression and using small panels of immunohistochemical markers to
carry out surrogate subtyping (1, 12), these data from triple-negative and Her2 disease
suggests that intrinsic subtyping may be an effective method to identify those patients in
which the toxicity of anthracyclines is justified.
In this study, we applied the PAM50 intrinsic subtyping assay to 476 retrospectively
collected tumor specimens from the NCIC-CTG MA.5 study, a prospective clinical trial that
randomized premenopausal women with node-positive breast cancer to receive adjuvant
chemotherapy with either cyclophosphamide-methotrexate-fluorouracil (CMF) or
cyclophosphamide-epirubicin-fluorouracil (CEF). We hypothesized that the benefit of
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substituting methotrexate for epirubicin would vary among the PAM50-defined intrinsic
subtypes.
Materials and Methods
Patients and treatment regimens
The MA.5 phase III trial was a randomized, controlled study of 716 premenopausal women
with node-positive breast cancers (7, 8).In brief, patients were accrued between 1989 and
1993 and randomized to receive either adjuvant CEF or CMF. The CEF regimen included 6
cycles of epirubicin 60 mg/m2 and 5-fluorouracil (5-FU) 500 mg/m2, both delivered
intravenously on days 1 and 8, with oral cyclophosphamide 75 mg/m2 daily on days 1
through 14. Patients on CEF also took prophylactic antibiotics throughout. The CMF
regimen included 6 cycles of methotrexate 40 mg/m2 and 5-FU 600 mg/m2, both delivered
intravenously on days 1 and 8, with oral cyclophosphamide 100 mg/m2 daily on days 1
through 14.
RNA preparation, quantitative reverse transcriptase PCR, and assignment of intrinsic
subtype
Four hundred and seventy-six tumors (67%) were obtained for quantitative reverse
transcriptase PCR (qRT-PCR)-based PAM50 gene expression testing. There were no
significant differences in the clinicopathologic characteristics between the qRT-PCR cohort
and the MA.5 study patients (Table 1). Supplementary Figure S1 summarizes the study
design as per ReMARK guidelines (13). Hematoxylin and eosin (H&E) sections from each
block were reviewed by a pathologist (T.O. Nielsen). Areas containing representative
invasive breast carcinoma were selected and circled on the source block. Using a 1.0-mm
punch needle, at least 2 tumor cores were extracted from the circled area. Details of RNA
preparation from paraffin cores, the qRT-PCR assay for the PAM50 panel and reference
genes, and how tumor samples were classified into luminal A, luminal B, HER2-E, basal-
like, and normal-like subtypes are as described previously (1, 2). ROR-S (ref. 1; risk of
relapse score using correlations to the subtype alone) risk score assignment was also
calculated for each tumor as described previously (1);
ROR-S = (0.05) × basal like + (0.12) ×HER2-E + (−0.34) × LumA + (0.23) × LumB
By prespecified cutoff points, patients were categorized as low risk if the ROR-S score was
less than 23, moderate risk if ROR-S score was between 23 and 53, and high risk if the
ROR-S score was 53 or more.
All genes expression tests and classifications were done without knowledge of or access to
the clinical outcome data, which is maintained at the NCIC-CTG central office
(Supplementary Fig. S1). All biomarker studies were approved by the Clinical Research
Ethics Board of the BCCA.
Clinical correlates of the intrinsic subtypes and risk classifiers
The intrinsic subtypes, risk classifier, and biomarker data were sent to the NCIC Clinical
Trials Group statistical centre for independent analyses of prespecified hypotheses (with
additional analyses considered “exploratory”). Primary outcomes for MA.5 were relapse-
free survival (RFS) and overall survival (OS). RFS was defined as time from trial arm
random assignment to any recurrences including local breast chest wall, regional, or distant
relapses. OS events were defined as death from any cause. The survival estimates for
intrinsic subtypes and risk classifiers were plotted using Kaplan-Meier curves and compared
by both log-rank and Wilcoxon tests. Univariable Cox proportional hazard regression
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models were used to obtain the HRs and associated 95% confidence intervals (CI) of single
covariates. Multivariable Cox regression analyses were used with treatments, intrinsic
subtypes, and their interaction as covariates, to determine the significance of the interaction
between treatment and intrinsic subtype. The multivariable Cox models were adjusted for
age (≥50 years vs. <50 years), number of positive lymph nodes (<4 vs. ≥4), estrogenreceptor
(ER) level (≥0 vs. <10 fmol/mg), type of surgery (total vs. partial mastectomy), and tumor
size (T1, T2, or T3). The associations of intrinsic subtypes with standard clinicopathologic
characteristics and biomarker expression were determined using the χ2 or Fisher exact tests.
All statistical analyses were conducted in R v.2.8.1 (http://cran.r-project.org) and SAS 9.2.
Immunohistochemistry, FISH, and tissue microarrays
Five hundred and forty-nine archival specimens (77%) were obtained for tissue microarray
construction; there were no significant differences in the clinicopathologic characteristics
between this cohort and the full MA.5 study set. Immunohistochemical staining methods
and interpretation of ER, progesterone receptor (PgR), and Her2 were prespecified and
conducted using published methods (12, 14). Her2/Neu and TOP2A amplifications were
measured by FISH as previously described (9, 10). To determine Her2 status in this study,
FISH data (amplification ratio ≥ 2.0) was used to segregate immunohistochemically
equivocal (2+) results. Biomarker expression was interpreted by pathologists blinded to
clinical outcome.
Results
Using the qRT-PCR–based PAM50 gene expression test, 31% of the 476 tumors were
classified as LumA, 23% as LumB, 22% as HER2-E, 20% as basal-like, and 4% as normal-
like subtypes. The normal-like samples were not considered further, as this class is used as a
quality control measure to assess the adequacy of tumor content in the specimen (1). The
clinical ER status was originally determined at accrual by the dextran-coated charcoal
(DCC) assay. AS expected, 88% of LumA and 96% of LumB tumors were ER positive
compared with50% of HER2-E and10% of basal-like tumors (Table 1). According to ER
status assessed by central immunohistochemistry conducted for this study, 90% of LumA,
95% of LumB, 44% of HER2-E, and 9% of basal-like were ER positive using a 1% cut off
point for positivity. ESR1 gene expression levels were measured by qRT-PCR and ER by
DCCcorrelated positively (r = 0.71, P< 0.0001). The LumB, HER2-E, and basal-like
subtypes were strongly associated with high-grade tumors. There were no significant
associations of subtypes with the number of positive lymph nodes, type of surgeries, or
adjuvant chemotherapy regimen trial arm assignment (Table 1).
Association of intrinsic subtypes by qRT-PCR PAM50 with RFS and OS
When analyzed on the entire cohort, intrinsic subtypes were significantly associated with
different RFS and OS estimates (Supplementary Table S1). These results therefore confirm
the intrinsic subtypes remain prognostic in patients uniformly treated with adjuvant
chemotherapy. In this study, the ROR-S low-risk groups (n = 79) were all classified as
LumA. For the ROR-S moderate-risk group (n = 202), 33% were LumA, 39% LumB, 21%
HER2-E, and 7% were classified as basal like. Within the ROR-S high-risk group (n = 174),
36% were classified as HER2-E, 46% as basal like, and 18% as LumB.The ROR-S risk
classifier was significantly associated with distinct survival differences (P < 0.0001; log-
rank test): the low-risk group (75% RFS and 94% OS at 5 years) had the most favorable
clinical outcome than the moderate-risk group (59% RFS and 80% OS at 5 years) and high-
risk group (51% RFS and 53% OS at 5 years), respectively (Supplementary Table S1).
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Within the CMF-treated cohort, intrinsic subtypes were associated with significantly
different RFS and OS (P < 0.0001, log-rank test, Table 2). Patients with HER2-E tumors had
the poorest clinical outcome, worse than each of the other subtypes (Table 2). The basal-like
subtype had RFS estimates comparable with those in patients with LumA or LumB tumors
in this nonanthracycline arm. Comparing the 2 ER-positive subtypes, LumB tumors had a
worse prognosis than LumA. The 3 survival risk groups defined by the prespecified ROR-S
risk classifier were significantly associated with distinct RFS and OS estimates (Fig. 1A and
B). The low-risk group (n = 41) had absolute 12% higher 5-year RFS and 16% higher 5-year
OS than the moderate-risk group (n = 101) and 29% higher 5-year RFS and 43% higher 5-
year OS than the high-risk group (n = 92).
In the CEF-treated arm, intrinsic subtypes showed less distinct differences for both
endpoints (P = 0.64, log-rank test, for RFS and P = 0.09 for OS, Table 2). Patients with
HER2-E, basal-like, and LumB subtypes had comparably poor clinical outcomes, whereas
those with the LumA subtype had the best prognosis (Table 2). In this CEF arm, the ROR-
S–defined risk groups had significantly different survival (Fig. 1C and D). The low-risk
group (n = 38) had absolute 20% higher 5-year RFS and 13% higher 5-year OS than the
moderate-risk group (n = 101) and 18% higher 5-year RFS and 38% higher 5-year OS than
the high-risk group (n = 82). Almost all events in the high-risk group occurred within 5
years, and differences between the moderate- and high-risk groups did not reach statistical
significance.
Selective treatment benefits across intrinsic subtypes
In the MA.5 study subset with paraffin blocks available for this study, there was a trend for
survival improvement for the anthracycline-containing regimen over the methotrexate-
containing control arm (Fig. 2) comparable in magnitude to that previously reported for the
trial as a whole. HER2-E tumors showed the greatest benefit from CEF versus CMF (Fig. 2),
with an observed 21% gain in 5-year RFS and 20% gain in 5-year OS (Fig. 3A and E). The
interaction between HER2-E subtype and anthracycline sensitivity was significant for both
endpoints (Fig. 2, P = 0.03). In contrast, basal-like tumors achieved no survival advantage
for CEF over CMF, with a reverse trend having an observed 10% higher 5-year OS for the
CMF arm (Fig. 3F). The treatment effect differences between the 2 luminal subtypes, which
differ markedly in expression of proliferation genes, were also compared. Results from the
multivariable Cox regression analysis suggested that patients with LumB tumors had a trend
for better survival when treated with CEF, whereas LumA tumors trended to better survival
when treated with CMF (Figs. 2, 3C, D, G, and H). However, the interaction test for
treatment by LumA and LumB subtypes was not significant (RFS, P = 0.25; OS, P = 0.11).
In summary, the relative observed RFS and OS risk reduction associated with CEF versus
CMF was 44% and 38% for HER2-E and 24% and 17% for LumB, respectively. On the
other hand, the relative observed RFS and OS risk reduction associated with CMF versus
CEF (i.e., the opposite pattern of drug sensitivity, favoring CMF) was 11% and 24% for
basal-like and 12% and 42% for LumA, respectively. Differences only reached statistical
significance for the HER2-E group.
HER2-E gene expression subtype and clinical Her2 status for predicting anthracycline
sensitivity
The HER2-E subtype by PAM50 was significantly associated with clinical Her2 positivity
(P < 0.001). Sixty-eight percent (71 of 105) of the HER2-E subtype tumors were clinically
Her2 positive by immunohistochemistry (IHC)/ FISH analyses. For the other subtypes, 6%
(9 of 145) of LumA, 7% (8 of 110) of LumB, and 2% (2 of 94) of basal-like were Her2
positive by IHC/FISH.
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Clinical Her2 status was previously shown to be a significant predictor of improved survival
for CEF over CMF in MA.5 (9), a result also observed in this study subset (Supplementary
Table S2). We therefore compared the accuracy and significance of the PAM50-based
HER2-E subtype and clinical Her2 status as biomarkers to predict patient outcome. Using
multivariable Cox regression analysis, the treatment interactions observed in the HER2-E
subtype remained significantly independent when adjusted with the clinical Her2 status
(Table 3). The treatment interactions in clinical Her2 status also remained independent when
adjusted with the HER2-E subtype status. These results suggest that clinical Her2 status and
gene expression HER2-E subtype, although correlated, are not equivalent, and moreover that
defining patients as HER2-E subtype by gene expression provides independent information
of potential clinical value beyond that obtained by Her2 testing alone.
We developed the post hoc hypothesis that the anthracycline benefit would be mostly
conferred within Her2+ tumors by those also assigned as HER2-E by PAM50. Consistent
with this hypothesis, the Her2+ HER2-E tumor subset treated with CEF had especially large
benefits in RFS (an absolute 40% gain in 5-year RFS) and OS (an absolute 35% gain in 5-
year OS) when compared with those randomized to CMF (Table 4). Among the clinical
Her2-negative/weak tumors, patients with HER2-E tumors by PAM50 did not appear to gain
benefit from CEF over CMF (Table 4). Although study numbers are small, these data
suggest that positive clinical Her2 combined with assignment to HER2-E PAM50 subtype
could be the best predictor for survival benefit of anthracycline substitution for
methotrexate. We carried out an exploratory analysis to examine further if there was a linear
relationship between a tumor's correlation to the HER2-E subtype and survival in each study
arm. Supplementary Figure S2 illustrates the relationship between benefit of CEF over CMF
with the tumor's relation to the prototypical HER2-E centroid as a continuous predictor.
Five-year predicted RFS and OS were estimated from a Cox model including the HER2-E
component of a tumor (i.e., the higher the HER2-E content present in a tumor, the higher the
HER2-E centroid value). This analysis shows a slight benefit of CMF over CEF when a
tumor anticorrelates with the HER2-E centroid and a more striking benefit of CEF over
CMF when a tumor positively correlates with the HER2-E centroid. The higher the content
of HER2-E in a tumor, the lower the 5-year RFS and OS rate when treated with CMF.
Discussion
Anthracycline-based chemotherapy regimens remain a commonly used adjuvant therapy for
high-risk early stage breast cancer, despite their significant toxicity profile, including
neutropenia, infection, secondary leukemias, and cardiotoxicity (15). Adjuvant anthracycline
polychemotherapy was showed to provide a 4% improvement in overall survival in
comparison with nonanthracycline chemotherapy in the 2000 EBCGTG meta-analysis (16).
There has been much research on biomarkers that could detect responsiveness to
anthracyclines. However, to date, there has been no published analysis on the use of intrinsic
subtyping to select specific adjuvant chemotherapy regimens.
In this study, we tested the predictive value of intrinsic subtyping in a cohort of patients
randomized to CEF- versus CMF-based chemotherapy. We observed that the HER2-E
intrinsic subtype, identified by the PAM50 assay, benefited the most from an anthracycline-
based adjuvant chemotherapy regimen. We were also able to subset the ER-positive tumors
into their component intrinsic subtypes, including luminal A and luminal B, and were unable
to detect any statistically significant survival gain in these subgroups when treated with
CEF. However, it is recognized that many of these subgroups were small and the power to
detect small clinical differences was limited.
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Trastuzumab is currently the standard of care for clinical Her2-positive tumors. One
limitation of this current study is that the MA.5 trial predates use of trastuzumab and so did
not use it for Her2-positive patients. Nevertheless, we have observed that the sensitivity of
clinical Her2þ tumors to neoadjuvant anthracycline-taxane–based regimens, even when
trastuzumab is given, is mainly contained within tumors of the HER2-E expression subtype
(17).
In fact, the choice of CMF versus CEF remains a highly relevant issue, even in the modern
setting of taxane and trastuzumab-based treatments. These latter treatments are not available
to many women in public health systems in the developing world where CMF and
anthracycline-based therapy remain the most widely adopted standard (e.g., <14% of
Brazilian patients receive taxanes; ref. 18). A recent report on meta-analysis of 3,452
patients for Her2 amplification and TOP2A from 5 randomized adjuvant trials that
compared anthracycline-based regimens with CMF regimens did not support the use of
anthracyclines only in patients with Her2-amplified or TOP2A-aberrated tumors (19). The
authors suggested that the interaction between anthracycline sensitivity and Her2 or TOP2A
status might be a quantitative relationship rather than a qualitative relationship. Here, our
post hoc analysis showed that a Spearman correlation to the HER2-E centroid (i.e., a
quantitative measurement of similarity to the average expression profiles of a typical HER2-
E tumor) can be a potential useful tool to estimate the tumor sensitivity for adjuvant CMF or
CEF (Supplementary Fig. S2). Our data showed that the relative sensitivity of anthracyclines
remained fairly constant across the spectrum of HER2-E subtype centroid similarity. On the
other hand, it appeared that there was a negative correlating relationship between adjuvant
CMF benefit with the HER2-E subtype centroid. Thus our findings corroborated the
potential predictive value of the HER2-E subtype centroid,as a quantitative measurement,to
identify anthracycline sensitive tumors in addition to the standard clinical assays such as
Her2 status.
Basal-like breast cancers represent a particular clinical challenge as they are both hormone
receptor and Her2 negative and therefore not sensitive to existing targeted therapies. Studies
of neoadjuvant chemotherapy in breast cancer show that clinical and pathologic response
rates tend to be high in basal-like cancers (3, 4, 20), supporting sensitivity of these tumors to
conventional chemotherapy. Our results suggest that anthracyclines may not be an essential
component of chemotherapy for the treatment of basal-like breast cancers. Patients with
these tumors who received CEF had a 32% relative increase in mortality compared with
those who received CMF. The 95% CI on the HR ranged from 0.7 to 2.5. Findings suggest
that CMF is likely equal to or better than CEF for these tumors, although it is possible that
CEF could be anywhere from 30% better than CMF to 50% worse for basal-like tumors.
Testing the hypothesis of lack of survival benefit from substituted anthracyclines in basal-
like tumors on a prospective phase III randomized trial does not seem to be practical:to
achieve 80% power for a 2-tailed test at alpha 0.05 to detect no clinical survival benefit
exceeding the 4% reported from the Oxford Overview (16), a total of 4,730 basal-like
tumors would need to be accrued. Therefore, we must consider accepting lower levels of
evidence than could be achieved from a prospective noninferiority clinical trial, by testing
the hypothesis on multiple retrospective studies of adjuvant CMF versus CEF-like regimens.
For instance, if validation results in additional CEF versus CMF trials (such as DBCG89D;
ref. 21) are consistent with MA.5, then the development of adjuvant regimens for basal-like
breast cancers based on multiagent chemotherapy including novel targeted agents may not
need to include an anthracycline as an obligatory component.
Luminal B breast cancers are highly proliferative ER-positive tumors which carry a
significantly worse prognosis than their counterpart ER-positive/luminal A tumors (12).
These luminal B tumors are chemosensitive and generally respond to cytotoxic drugs. Paik
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and colleagues reported that the Oncotype DX high-risk group had a large benefit from
additional adjuvant CMF with an absolute decrease of 28% in distant relapse risk when
compared with the tamoxifen only arm in the NSABP-B20 trial (22). Our study provides
information that there was no major survival difference between adjuvant anthracycline-
containing versus nonanthracycline adjuvant chemotherapy regimens among luminal B
tumors, although there was a trend to better survival on CEF. Luminal A tumors,
representing 31% of patients in this study, do appear to represent another large subset of
patients in whom anthracycline-based treatment may be dispensed with.
Another unique feature of our study was the assessment of prognostic value of ROR-S risk
classifier for adjuvant CMF and CEF regimens, respectively. The ROR-S classifiers were
previously developed and defined on the basis of the biology of intrinsic subtypes using an
independent cohort of node-negative, untreated patients (1). In this report, we validated that
the 3 predefined risk groups were significantly associated with survival differences for both
treatment arms, most distinct within the 5 years. Although ROR-S risk groups were highly
associated with intrinsic subtype classifiers, our data showed that ROR-S could also provide
prognostic information for clinicians to estimate the survival rates of a patient for adjuvant
CMF and CEF.
In conclusion, we confirm that intrinsic subtypes provide independent predictive value to
anthracycline versus nonanthracycline chemotherapy beyond clinical Her2 status. These
data suggest that the benefit of CEF over CMF is largely limited to patients with the HER2-
E gene expression pattern and Her2+ IHC/FISH status. The chemotherapy-sensitive basal-
like tumors showed no added benefit for CEF over CMF, suggesting that nonanthracycline
regimens may be adequate in this subtype although further investigation is required.
Supplementary Material
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Molecular subtypes of breast cancer may differ in their responsiveness to specific
chemotherapy regimens. Here, we tested the predictive value of intrinsic subtypes on
clinical trial specimens from premenopausal women with node-positive breast cancers,
who were randomized to anthracycline (CEF) versus nonanthracycline (CMF)
chemotherapy. We found that intrinsic subtypes by qRT-PCR–based PAM50 assay,
particularly the HER2-E subtype, can provide significant additional predictive value to
select patients who benefit the most from an adjuvant anthracycline-based chemotherapy
regimen. In the chemotherapy-sensitive basal-like tumors, no added benefit was detected
with anthracycline substitution, suggesting that nonanthracycline regimens should be
30% of the patient population in this study, also did not show a preferential sensitivity to
CEF over CMF. Our results suggest that patients with basal-like and luminal A tumors
might be safely spared of anthracycline-based chemotherapy regimens and their side
effects.
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RFS and OS by ROR-S risk of relapse score, stratified by adjuvant treatment arm (A and B,
CMF; C and D, CEF).
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Multivariable Cox regression analysis adjusted HR plots by PAM50 intrinsic subtype,
adjusted for clinicopathologic variables.
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Univariate RFS and OS Kaplan–Meier plots of treatment arms, CEF versus CMF, stratified
by intrinsic subtypes (A–D, RFS; E– H, OS).
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Table 3
Multivariable Cox regression analyses of clinical Her2 status and HER2-E gene
expression subtype, to predict anthracycline sensitivity (superiority of adjuvant CEF over
CMF)
Interaction term P Adjusted for
RFS HER2-E by PAM50 × treatment 0.016 Clinical Her2 status
Clinical Her2 × treatment 0.0007 HER2-E by PAM50
OS HER2-E by PAM50 × treatment 0.012 Clinical Her2 status
Clinical Her2 × treatment 0.0008 HER2-E by PAM50
NOTE: All models included the standard clinicopathologic variables.
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